Pregnancy in women with metabolic disorders such as diabetes has been well studied, but relatively little is known about the reproductive ability of women with inborn errors of metabolism. This is due to the fact that identification and treatment for these diseases have only been accomplished within the last 2 decades. The best known and well studied of the inborn errors is phenylketonuria (PKU) (McKusick 26160) . Most women with PKU who have normal intelligence are still too young for marriage and child bearing. Thus the natural history of the maternal PKU syndrome, as we know it today, deals primarily with pregnancy outcome in a group of mentally retarded PKU women who conceived while on an unrestricted phenylalanine intake (Woolf et al., 1961; Mabry et aI., 1963; Fischet al., 1966; Forbes et al., 1966; Frankenburg et al., 1968; Zaleski et al., 1979) . The excellent reviews by Mabry (1978) and Lenke and Levy (1980) have detailed the natural history of poor reproductive outcome in these women. The clinical challenge today is to develop an approach which could assure an improved child bearing experience for women with PKU.
Our experience suggests that maternal phenylalanine levels of 240-480/2mol/L are not detrimental to fetal outcome (Koch and Blaskovics, 1982) . Three mothers in this range gave birth to 9 children with intelligence within the normal range. On the other hand, the one woman with phenylalanine concentrations above this range (600-900/zmol/L) had 4 retarded children.
During pregnancy there is a positive gradient of phenylalanine from mother to fetus. This has been documented with simultaneous maternal and cord blood specimens for amino acid analysis. Since the PKU woman does not provide sufficient tyrosine to the fetus, tyrosine supplementation has been recommended in addition to restricting phenylalanine intake to achieve successful pregnancy outcome (Komrower et al., 1979) .
DIETARY THERAPY
There remain many unsolved problems (Buist et al., 1979; Levy and Waisbren 1983) and there is legitimate divergence of opinion concerning dietary therapy for maternal HPA. The reports by Allen (1968) , Komrower and colleagues (1979) , Smith and colleagues (1979) , Nielson and colleagues (1979) and Tenbrink and Stroud (1982) showed improved fetal outcome when treatment with the phenylalanine restricted diet was instituted shortly before or after conception. The recent summary of the outcome of 34 such pregnancies by Lenke and Levy (1982) is not conclusive about the efficacy of dietary therapy. Lenke and Levy (1980) reported results of their international survey of 524 pregnancies in 155 women with PKU and HPA. Restriction of phenylalanine intake prior to conception occurred in 3 pregnancies and 31 received therapy after pregnancy was established. Among the 121 untreated women the frequency of mental retardation associated with microcephaly in their offspring was increased over those born to women treated during pregnancy. 95% of mothers with blood phenylalanine levels greater than 1200/xmol/L had at least one mentally retarded child. However, the information on the treated pregnancies was fragmentary, often incomplete and largely retrospective. Thus is was not possible to conclude that dietary therapy post-conception was therapeutic (Lenke and Levy, 1982) .
Based on the reported evidence, the prudent course is to institute the phenylalanine restricted diet prior to conception as suggested by Nielson and colleagues (1979) .
GENERAL ASPECTS OF THERAPY
Providing care for a pregnant PKU woman includes medical and dietary treatment, health education and emotional support. Close supervision of the diet, frequent monitoring of serum phenylalanine and serial obstetrical evaluations are essential to document the progress of a woman's pregnancy. Health education should emphasize the effects of maternal PKU on the unborn infant, as well as the physiological changes during pregnancy. The mother's level of intelligence and her emotional maturity should be taken into account when counselling. Providing the mother with support and encouragement during the pregnancy establishes positive rapport helpful in maintaining appropriate dietary treatment and compliance with clinical care. Cooperation between the obstetrician and the nearest medical centre offering clinical PKU services is preferred for the provision of comprehensive care. Members of the clinical team managing a pregnant woman with PKU can establish positive rapport through ongoing education and support, to encourage successful dietary therapy and pregnancy outcome.
A protocol for the nutrition support of maternal PKU was recently developed for the Maternal PKU Collaborative Study between the United States and Canada, sponsored by the National Institute of Child Health and Human Development. General nutritional guidelines had been developed and published earlier (Acosta et al., 1982) .
The role of trace elements in the diet of PKU women treated with the phenylalanine restricted diet is unclear because the requirements for normal pregnancy are not well established (Metcoff et al., 1981) . Recommended dietary allowances for man have been determined for 3 (iodine, iron and zinc), and ranges of 'estimated safe and adequate daily dietary intakes' for 6 others (chromium, copper, fluoride, manganese, molybdemun and selenium) (Dairy Council Digest, 1982) . Some of these data are based on animal data and thus their application to pregnancy outcome is difficult to assess. Recently data on zinc requirements in pregnancy suggested that this element may play a critical role (Mertz, 1981; Sever, 1982) . Zinc levels during pregnancy are lower than those in non-pregnant women. The 25% decrease in zinc levels in the last trimester of pregnancy is probably physiological because of increased blood volume, decline in serum albumin in levels and raised levels of endogenous oestrogens (Hambidge and Mauer, 1978) .
In addition to these decreases in zinc levels, the pregnant woman with PKU is restricted in meat intake and other dietary sources of available zinc: supplementation of zinc to the recommended intake during pregnancy is therefore indicated. Further research and prospectively collected data are required to determine the significance of trace elements in the treatment of maternal PKU.
EXPERIENCE AT THE CHILDRENS HOSPITAL OF LOS ANGELES
Publications prior to 1970 delineated the course of women with hyperphenylalaninaemia cared for at this institution (Forbes et al., 1966; Frankenburg et al., 1968) . The outcome despite our best efforts at treatment were poor. Since those publications appeared, 5 additional pregnancies in PKU women have been treated. It is gratifying to report that the most recent therapeutic efforts have been more rewarding. The better results seen in our last 5 pregnancies are no doubt related to earlier institution of the phenylalanine restricted diet, but may also be due to more careful attention to nutritional care, trace element and tyrosine supplementation.
Case Report 1
The mother is a 19-year-old in whom PKU was diagnosed and treated at 5 days of age. She continued diet restriction until aged 8 years and her intelligence quotient on the Wechsler Intelligence Scale for Children (WlSC) at age 15 was 90. After dietary discontinuation, her blood phenylalanine levels usually ranged above 1200 ~mol/L. She altended public school classes for the educationally handicapped and graduated from high school at the age of 18 years.
At the time of the suspected pregnancy, a blood phenylalanine level of 1308 /zmol/L was noted. The pregnancy was not confirmed until 7 weeks later because of failure to keep clinic appointments. This woman therefore did not begin the phenylalanine restricted diet until about 12 weeks gestation. Initially Phenyl-Free* was offered: this product made her nauseous and subsequently Lofenalac* was prescribed. Thereafter, she was able to tolerate the phenylatanine restricted diet for the remainder of her pregnancy.
Blood phenylalanine levels were usually between 600-780/~mol/L and were consistently above the recommended range. Every effort made to lower these high levels was unsuccessful. She was not competent in keeping dietary records: thus it was unclear what her protein intake was during the pregnancy. Supplementation of the mother's diet with tyrosine (50 mg kg -a day -a) was started at the beginning of the 14th week of pregnancy. Serum tyrosine levels rose to 200 tzmol/L and she exhibited a maculopapular rash. The dose was reduced and the rash disappeared. Subsequently she tolerated 50 mg kg -1 day -1 until delivery. The maternal phenylalanine level on the day of delivery was 344/xmol/L. In contrast, the infant's cord blood level was 786/xmol/L, but dropped sharply within 19 hours to 78 tzmol/L. Simultaneous amniotic fluid phenylalanine level was 276/~mol/L on the day of delivery. Arterial cord blood was 93 ~mol/L. Simultaneous plasma tyrosine level at delivery was 47/zmol/L, and the amniotic fluid level was 33/zmol/L. Physical examination of the newborn infant revealed a slightly lethargic male who appeared normal. The head circumference measured 31.5 cm, length 50 cm and weight 2863 g. The anterior fontanelle was small, measuring only 1.5 cm in width.
An ultrasound evaluation suspected a small fetal head circumference at the end of the 2nd trimester. A small head circumference (-2 SD) persisted to 4 years of age. Developmental assessment at the time reported an IQ of 89 and immature speech development. This child is now nearly 5½ years of age. There are no other abnormal physical findings.
Case Report 2
She was an only child born to young, unstable parents. Her mother was mildly retarded with an IQ of 71 on the Wechsler Adult Intelligence Scale (WAIS). At 5½ months of age, a routine diaper screening test for phenylpyruvic acid was reported as positive and subsequently a blood phenylalanine level of 1860/zmol/L was recorded. Due to problems with dietary treatment, she was placed in foster care. At age 13 years she removed herself from the phenylalanine restricted diet. She attended regular public school, but did not graduate from high school.
At age 18 years, she returned to our clinic when she discovered that she was pregnant. This pregnancy ended in a spontaneous abortion at 10-12 weeks gestation. Although she was aware of the need for the phenylalanine restricted diet and was sexually active, she was reluctant to start dietary treatment prior to conception.
She subsequently became pregnant at age 20. She notified our staff when she was about 12 weeks pregnant and resumed dietary restriction at that time. The initial blood phenylalanine level was 1080/~mol/L. During this pregnancy, the phenylalanine concentrations averaged 492/xmol/L (range 264-708). Ultrasonography on several occasions revealed a normal sized fetus. Tyrosine supplementation of 4 ~/day was started at 20 weeks gestation. This was arbitrarily increased to 6 g/day by 26 weeks and to 8 g/day at 35 weeks gestation. In addition to the tyrosine, a mineral supplement was commenced at 20 weeks gestation. Serum zinc, iron and copper were monitored monthly. Labour was induced during the 38th week of pregnancy. The baby was delivered in good condition, weighing 3062 g and measuring 51 cm in length with a normal head circumference of 34cm.
This infant appeared normal at birth and continued to grow normally in both height and weight. There were no physical findings of microcephaly or cardiac disorders. The last developmental assessment at 30 months of age reported a DQ of 84 on the Gesell Developmental Test. This child is currently 3 years old.
Case Report 3
This pregnancy occurred in the same woman as reported in case 2. This time however, the mother initiated the phenylalanine restricted diet when she realized she was pregnant, at 6 weeks gestation. Her blood phenylalanine levels averaged 588/zmol/L (range 126-1062/zmol/L). She went into spontaneous labour at 35 weeks gestation and delivered a 2551 g mate infant at home. His head circumference was 32 cm and his length was 44cm. These birth measurements were consistent with the gestational age. The infant appeared normal at birth and no abnormal physical findings have been identified to date.
The child is now 22 months old. Growth measurements for length, height and head circumference have consistently been less than the 5th percentile, but are proportional for size. His small size is probably related to the mother's small stature.
Case Report 4
This woman was born to an unstable marriage. When it became clear that she was mentally retarded, she was evaluated in a child development clinic at age 2½ years, when the diagnosis of PKU was made and a phenylalanine restricted diet initiated. At age 4 years her estimated IQ on the Stanford-Binet Intelligence Scale was 40. Because of her unstable family environment since early infancy, she was subsequently placed in a foster home where she continued on phenylalanine restriction and attended special classes in school. She continued to improve intellectually and by age 14 years her IQ on a WISC was 98. She discontinued dietary therapy at age 13 years. She attended special education classes and completed the 12th grade.
She conceived twice off dietary therapy at age 19 years and elected to have therapeutic abortions. Her blood phenylalanine levels off treatment ranged between 1014-1710/~mol/L. Shortly thereafter, she had a spontaneous abortion while starting on a phenylalanine restricted diet. She remained on dietary treatment and conceived 3 months later. Her blood phenylalanine levels during the pregnancy averaged 528/xmol/L (range 324-1208). Ultrasound at 26 weeks revealed twins, one of whom had a possible congenital cardiac defect. The twins were delivered by caesarian section at 35 weeks gestation due to premature onset of labour.
At birth, twin A appeared developmentally normal for physical growth, with a weight of 1729g, length 43 cm, and head circumference 29.5cm. No cardiac disorders or microcephaly were identified in this child. He required a tracheostomy at 2 months of age due to tracheal stenosis following severe bronchitis and pneumonia. Additionally, he had an endotracheal tube placed for less than 24 hours, a short time after birth. Gesell testing at 13 months of age reported a DQ of 98. He is currently 27 months old.
At birth, twin B exhibited a loud systolic murmur, but the infant appeared normal otherwise. The weight was 1843 g, length 43 cm and head circumference 29.5 cm. Further diagnostic cardiac studies confirmed the presence of an endocardial cushion defect with marked mitral valve deformity. Surgical correction was attempted when his cardiac condition could not be managed. Post-operatively, his condition deteriorated. He had a severe lesion involving the outflow tract of the left ventricle. This infant died at 5 months of age.
Case Report 5
The mother in this case was the mother of the twins reported above. She had a therapeutic abortion within 3 months of the birth of the twins. During the subsequent year, she became pregnant with case 5. She restarted the phenylalanine restricted diet at 3 weeks gestation and maintained fairly good control, averaging 552/zmol/L (range 222-960). At 39 weeks gestation, she delivered a healthy-seeming boy weighing 3298 g, measuring 50 cm in length and 33 cm in head circumference.
A fetal echocardiagram revealed an atrial septal defect at 22 weeks gestation. However, it was thought not to be as severe as in the previous twin. On physical examination at birth, no audible murmur was detected. An echocardiagram completed during the 1st week of life did confirm a small atrial septal defect: however, by 1 month of age the defect resolved without medical or surgical intervention. This child is currently 7 months old. He has been referred for a neurological evaluation due to persistent poor head control. Developmental assessment has not been completed. The child is alert, socially responsive and is growing well.
SUMMARY OF CLINICAL FINDINGS
The 3 PKU women reported here gave birth to 6 liveborn males. The PKU mother who started dietary treatment post-conceptionally had one child with severe cardiac defect and one with mild cardiac defect which resolved without intervention. However, this infant may have delayed neurological development and needs further evaluation. The PKU mother with blood phenylalanine above 600/xmol/L during her pregnancy had a son with persistent small head circumference at -2 SD. The children of the remaining PKU mother appear to be developing normally.
The 4 children who completed developmental testing are functioning in the borderline to average range of intelligence. However, the offspring will require long-term follow-up for accurate developmental assessment. School performance and learning disorders are difficult to determine from the early developmental assessments. Environmental factors such as parenting skills and socio--economic status will also have an impact on the outcome of these offspring.
DISCUSSION
It is clear that maternal PKU poses a serious risk to fetal development in the absence of dietary restriction of phenylalanine. The degree of fetal risk with therapy is as yet unclear, but most believe that phenylalanine restriction is beneficial. To assess the degree of risk, the National Institute of Child Health and Human Development has initiated a study involving the United States and Canada. The Medical Genetics Division at Childrens Hospital of Los Angeles was selected as the coordinating centre for the project, with 4 regional contributing centres encompassing 50 States and the District of Columbia (Figure 1 ). The research design is prospective, longitudinal and observational in nature, and will attempt to include 200 hyperphenylalaninaemic (HPA) pregnancies and their offspring. Women with blood phenylalanine levels persistently greater than 240/~mol/L, on an unrestricted diet, would be eligible.
The treatment plan will consist of: (1) provision of adequate nutrition during pregnancy (2) offering the phenylalanine restricted diet to HPA women with blood phenylalanine concentrations consistently greater than or equal to 600/.~mol/L (3) aiming to maintain blood phenylalanine concentrations between 120-600/~mol/L (4) supplementation with tyrosine and trace elements as medically indicated.
The research questions that the study is designed to answer are the following: (1) does the phenylalanine restricted diet reduce the frequency of mental retardation, spontaneous abortion, low birth weight, congenital malformations, neurological and behavioural impairment reported in pregnancies of HPA mothers who were on unrestricted phenylalanine intake during pregnancy? (2) is pregnancy outcome in HPA women who restrict phenylalanine intake during pregnancy comparable to that of non-HPA women? (3) is pregnancy outcome in HPA women related to maternal phenylalanine levels during pregnancy? (4) is gestational age, at the onset of intervention, predictive of fetal outcome? (5) are there beneficial effects of starting diet prior to conception? (6) what are the levels of tyrosine and trace elements during pregnancy and what are the effects on pregnancy outcome of supplementation if levels are found to be reduced?
In order to have demographically and genetically similar groups of non-HPA women to whom subjects may be compared, the study will follow prospectively Additional comparison groups will include (1) prospective evaluation of the pregnancies of the mates of HPA males, (2) prospective evaluation of offspring from previous pregnancies of HPA subjects, and (3) historical data on untreated HPA pregnancies from the 1980 Lenke-Levy survey.
In an observationa~ study such as the present one, many extraneous factors could contribute to observed differences between subjects and comparison groups. Some are accounted for in matching criteria for controls. Others will need to be routinely assessed and controlled for at the time of data analysis. Among this latter group are parental intelligence and head circumference, socio--economic status of the family, nutritional status apart from phenylalanine level prior to and during pregnancy, and maternal exposure to teratogens, such as drugs, tobacco and alcohol.
The very nature of long-term collaborative studies calls for dedication and selfsacrifice for the research effort, by the families and many individuals contributing to the data collection and analysis. The present study began on 1st May 1984, and has completed its organizational phase. Subject enrollment commenced on 1st November 1984. To date, 15 pregnancies have been followed and 25 more PKU women enrolled who are planning pregnancies.
It is hoped that the study will allow us to determine what phenylalanine level during pregnancy will maintain normal fetal development, whether preconceptual phenylalanine restriction is necessary, and whether supplementation with tyrosine and various trace elements such as zinc are necessary for normal pregnancy outcome.
In this early phase of the study most of the enrolled women are mildly retarded or borderline in intelligence. This problem hopefully will resolve as the study progresses and more women are enrolled with normal intellectual ability.
